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ORIGINAL ARTICLE

Laryngeal soft tissue sarcoma: A systematic review and
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Abstract
Background: Laryngeal sarcoma is rare. We performed a systematic review
and individual patient analysis to evaluate the patterns of care, prognostic factors, and role of radiotherapy in laryngeal soft tissue sarcoma.
Methods: A systematic search on PubMed and Google scholar was done. An
individual patient data analysis was done.
Results: Of the 300 cases of laryngeal sarcoma, 80% underwent surgery. 44%
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underwent larynx preservation surgery and 25% received radiotherapy with
surgery. Median progression free survival (PFS) was 48 months and overall
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survival (OS) of 224 months for the entire cohort. Patients with large primary,
cartilage invasion, and positive margins had numerically worse PFS. Cartilage
invasion and primary tumor size >3 cm were the most common risk factors
for adjuvant radiation therapy. Patients receiving radiotherapy were not associated with better survival.
Conclusion: Laryngeal sarcoma associated with a good survival. Larynx preservation surgery is feasible in nearly half patients. Adjuvant radiotherapy may
be warranted in patients poor prognostic factors.
KEYWORDS
larynx, patterns of care, radiotherapy, sarcoma

1 | INTRODUCTION
Head and neck is an unusual site for soft tissue sarcoma
and accounts for less than 10% of all sarcomas.1,2 Laryngeal
soft tissue sarcoma (LSTS) is quite rare and accounts for less
than 1% of laryngeal tumors.1,3 Owing to rarity, information
on histology, clinical features, and treatment options are
sparse. Management of laryngeal sarcoma poses unique
challenge for all relevant specialities. Respiratory distress or
stridor being the commonest presentation, many patients
require emergency tracheostomy and unplanned surgery.
Unlike other sites of soft tissue sarcoma, obtaining adequate
Head & Neck. 2021;1–7.

surgical margins in larynx often requires total laryngectomy
and thus complete functional loss. This unfortunately goes
against the standard practice in soft tissue sarcoma of organ
preservation surgery followed by adjuvant radiation. In
patients who undergo organ preservation surgery, role of
adjuvant radiation and chemotherapy is also inconclusive
in laryngeal sarcoma. There is also limited information on
patterns of recurrence. Present systematic review and individual patient data analysis are aimed at identifying patterns of care, comparing effect of organ preservation
surgery versus total laryngectomy and effect of adjuvant
therapy on survival and recurrence patterns.
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1.1 | Methodology
A comprehensive search of PubMed and Google scholar
with the following MesHand text terms “larynx sarcoma,
laryngeal sarcoma, larynx non-epithelial tumor, larynx AND
sarcoma, laryngeal AND sarcoma” was done independently
to retrieve all possible publications in laryngeal sarcoma by
authors AR and YI. The search engines were screened till
September 2020. Search result was restricted to articles published in English language and related to human studies
only. After collecting patient data with laryngeal sarcoma
from systematic search, duplicate entries were removed by
mutual discussion. After the initial search, the abstracts were
read, and relevant publications were sorted for extraction of
data. Individual patient information was retrieved from full
papers of case reports and case series. Abstracts were used to
obtain information and corresponding authors were communicated by email to retrieve information, wherever full
paper could not be retrieved. References in articles were
cross-checked not to miss any article in our search process.
Individual patient data were entered in a pre-designed excel
sheet. PRISMA flow chart depicts data synthesis from the
eligible studies (see supporting information). Categorical variables were summarized by frequency and percentage and
quantitative variables by the median and range. Overall survival (OS) was calculated from the date of diagnosis to the
date of documented death respectively. Statistical analyzes
were done using the MedCalc version 19.2.6 software. Univariate analysis was done using the log-rank test and multivariate analysis done using the Cox-regression analysis. A pvalue of <0.05 was considered significant.
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TABLE 1
sarcoma

Demographic and treatment features of laryngeal

Demographic features

No. of
patient (n)

Percentage
(%)

Laryngeal soft tissue sarcoma
(LSTS)
Non-rhabdomyosarcoma
non-Ewing's laryngeal
sarcoma (NRNELSTS)

300

81

Ewing's
/rhabdomyosarcoma

72

19

Males

222

73.6

Females

53

18

Not described

25

8.3

Hoarseness

130

44

Stridor/respiratory distress

46

16

Dysphagia

20

6.7

Swelling/mass

7

2

Others

23

7

Unknown

74

20

Supra-glottis

116

39.6

Glottis

96

33

Sub-glottis

15

5

Larynx-NOS

50

15

Not described

29

7

Synovial sarcoma

64

22.7

Leiomyosarcoma

57

19.7

Fibrosarcoma

49

16

Liposarcoma

46

14.7

Yes

240

80

No

28

9

Not described

32

11

Radical

135

56

Conservative

105

44

Sex (n = 300)

Presenting complaints
(n = 300)

Sub-sites (n = 300)

Histology

2 | R E SUL T S
2.1 | Patient demography and treatment
details
Non-rhabdomyosarcoma non-Ewing's laryngeal sarcoma
(NRNELSTS) constituted 81% (n = 300) of all LSTS
(n = 372). Median age of presentation was 53 years
(range: 2 months–87 years). There was a clear male preponderance seen in NRNELSTS (male to female ratio of
4:1). Most common presentation was hoarseness seen in
44% of patients and16% patients presented with respiratory distress or stridor (Table 1). Median symptom duration was 4 months (range: 2 days–72 months). Smoking
history was present in only 5% patients (n = 15). Supraglottis (n = 116) was the commonest location of tumor
followed by glottis (n = 96). Cartilage invasion at presentation was documented in 13 (4.3%) patients only. Three
(1%) patients presented with metastatic disease. Commonest histology was synovial sarcoma (n = 64) followed

Surgery (n = 300)

Extent of surgery (n = 240)

Radiotherapy
Radical
PORT

12
68/240

27

Radical surgery

38/135

28

Conservative surgery

26/105

25

PORT following
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by leiomyosarcoma (n = 57) and fibrosarcoma (n = 49)
(Figure 1). A total of 240 (80%) patients underwent surgery for treatment of NRNELSTS while 28 (9%) patients
did not undergo surgery. 105 (44%) patients underwent
larynx preservation surgery while 135 (56%) patients
underwent total laryngectomy. Positive or close margins
were found in six patients. Adequate information on
treatment was not available in 11% patients. Twenty-six
(25%) patients who underwent larynx preservation surgery received adjuvant radiation while 38 (28%) patients
who underwent total laryngectomy received adjuvant
radiation. Median dose of adjuvant radiation was 60 Gy
(range: 33.5–75 Gy). Twelve (44%) of 27 patients, who did
not undergo surgery, were treated with radiation. The
median dose of definitive radiotherapy was 60 Gy
(Range: 19.3–76.5 Gy). Adjuvant chemotherapy was given
in five patients while neo-adjuvant chemotherapy was
used for one patient. Demographic and treatment details
are summarized in Table 1.

3

2.4 | Effect of radiationand type of
surgery on progression free survival and
overall survival
There was no difference in PFS or OS based on type of surgery, that is, conservative versus radical surgery on univariate analysis (Figure 3). There was no difference in OS or
PFS on addition of radiotherapy to surgery (Table 2)
(Figure 4). But chi-squared test showed higher proportion
of patients with above prognostic factors received radiation
(Table 3). Multivariate analysis failed due to lack of events.

2.5 | Recurrence patterns in laryngeal
sarcoma
A total of 67 (23%) patients experienced documented
recurrence. Local or loco-regional recurrence was seen in

2.2 | Survival analysis
Median progression free survival (PFS) of entire cohort
was 48 months (95% CI: 29–84 months). Median overall
survival (OS) was 224 months (95% CI: 224–396 months)
for the entire cohort (Figure 2).

2.3 | Prognostic factors
On univariate analysis histology, size ≥3 cm, cartilage
invasion, and positive margin were associated with
numerically worse PFS. Median PFS for patients with
cartilage invasion was 16 months versus 36 months for
patients with no cartilage involvement (p = 0.646). Location of primary was not found to be a prognostic factor
(Table 2).

F I G U R E 2 Kaplan Meier curve comparing progression free
survival between radical and conservative surgery [Color figure can
be viewed at wileyonlinelibrary.com]

F I G U R E 1 Kaplan Meier curve representing overall and progression free survival of entire cohort [Color figure can be viewed at
wileyonlinelibrary.com]
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TABLE 2

Univariate analysis of prognostic and treatment factors on survival

Factors

Median
PFS
(months)

95% CI
(months)

p-value

Median
OS
(months)

95% CI
(months)

p-value

Remarks

p = 0.045

Fibrosarcoma worse
OS than
leiomyosarcoma or
synovial sarcoma

Histology
Fibrosarcoma

22

10.5–22

Leiomyosarcoma

24

8–24

Synovial
sarcoma

36

12–51

Yes

16

4–113

No

36

16–36

50
p = 0.563

38–224

Not
reached
Not
reached

Cartilage invasion
p = 0.646

Not
reached
50

10–50

69

32–69

24

24–24

p = 0.484

Cartilage invasion
associated with
numerically worse PFS

p = 0.618

Positive margins
associated with
numerically worse OS

Margin status
Negative

Not reached

Positive

36

p = 0.286
6–36

Size
<3 cm

Not reached

>3 cm

29

p = 0.153
16–32

Not
reached
39

p = 0.558
30–39

Conservative
surgery
No RT
RT

Not reached

p = 0.220

36

14–51

No RT

29

15–60

RT

36

16–60

Not
reached

p = 0.767

Not
reached

Radical surgery
p = 0.955

36 patients while distant metastases occurred in only
20 patients. Overall median time of recurrence was
12 months (range 1–216 months). Median time for local
and distant recurrence was similar (12 months). Commonest site of distant failure was lung (n = 14) followed
by bone (n = 6). For 27 (75%) of 36 patients of locoregional failure, salvage surgery was attempted.

3 | DISCUSSION
Sarcomas (non-RMS, non-Ewing's) are commonly found
to arise from the extremities. Malignant tumors, which
arise from head and neck, are usually of epithelial origin
and squamous cell carcinoma (SCC) is the most common

Not
reached

p = 0.716

Not
reached

histology.4,5Sarcomas make a very small fraction of head
and neck tumors. As laryngeal sarcoma is less common,
its behavior, optimum treatment, and outcome remain
elusive and merits to be looked in. As we embarked on
the systematic review and individual patient data analysis, we found only a handful of cases (372 cases) of laryngeal sarcoma. Point should be made that nearly 80% of
laryngeal sarcomas are non-rhabdomyosarcoma nonEwing's. We restricted our further analysis to NRNELSTS
as treatment and prognosis vary considerably in Ewing's
sarcoma and rhabdomyosarcoma. The present analysis
clearly highlights that LSTS present in the sixth decade of
life with hoarseness (44%), which is quite like the presentation of SCC of larynx.5 Age of presentation in our study
is like that found in a SEER database analysis where in
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F I G U R E 3 Kaplan Meier curve comparing overall survival after radiotherapy with radical and conservative surgery [Color figure can be
viewed at wileyonlinelibrary.com]

F I G U R E 4 Graphical representation
of distribution of laryngeal sarcoma
histology [Color figure can be viewed at
wileyonlinelibrary.com]

T A B L E 3 Chi-squared test to assess selection bias of patients
for radiotherapy (RT)
Prognostic factors

No RT

RT given

No

3

7

Yes

10

9

Negative

16

13

Positive

1

4

< 3 cm

18

8

>3 cm

9

18

p-value

Cartilage invasion
p = 0.2043

Margin
p = 0.1188

Size
p = 0.0096

>75% patients presented between 50 and 80 years of age.6
Stridor was the presenting complaint in 16% cases and
another 6% presented with dysphagia, but presentation
with a lymph node was quite rare seen in <5% cases.
Contradictory to our finding, the SEER database analysis
found >80% patients presenting with lymph nodes. One

possible reason could be a higher percentage of carcinosarcoma in the SEER database analysis and different distribution of various histologies between the two studies.
Other possible reason could be reporting bias in various
case reports and series in our study. Male patients were
affected four times more commonly than females in the
present study, which closely corroborates with SEER data
as well as in large single institutional series of laryngeal
sarcoma6-8 Only 5% cases had history of smoking in our
analysis. Hence, it appears reasonable to consider a differential of LSTS whenever a non-smoker is being evaluated for hoarseness without any palpable neck node and
a lesion is found in the larynx. The present analysis also
highlights that these tumors arise equally from supra
glottis larynx or glottic larynx and 13 patients had documented cartilage invasion. Hence, it appears important to
include MRI of the neck to diagnose the extension of the
disease. The most common site of metastases appears to
be lung followed by bone. Therefore, CT chest in the initial work up may be warranted and clinicians must have
in mind the chance of bone metastases during follow
up. The dictum in recent years for laryngeal cancers has

6

F I G U R E 5 Evaluation and management algorithm laryngeal
soft tissue sarcoma [Color figure can be viewed at
wileyonlinelibrary.com]

been to attempt functional preservation with conservative
surgery or radiotherapy. However, such approach may
not be suitable for sarcoma. Surgery forms the cornerstone of therapy in LSTS as the analysis found surgical resection rate of nearly 80%. The most important highlight
is that even in such rare disease nearly 44% patients
underwent a larynx preservation surgery without excess
R1 resection. Conservative surgical approach may also be
further supported as PFS was no different compared to
those of radical approach. This finding is further
supported by similar findings from the SEER database
analysis.6 This may be attributed to early development of
symptoms and early diagnosis unlike extremity STS.
Adjuvant radiation, for extremity STS, is often advocated
for high grade, deep seated and larger tumors. In the present analysis, nearly 25% patients from both conservative
surgery group and laryngectomy group received adjuvant
radiation to a dose of 60 Gy. On analysis of impact of
adjuvant radiation on survival outcome, we found no
improvement in log rank test. However, in chi-square
analysis significantly higher number of patients with
larger (>3 cm) tumor received adjuvant radiation, which
appears to have equated survival outcome of poor risk
patients with that of good risk patients and this may be
considered a positive effect of adjuvant radiation. Point
should also be made that nearly 50% of evaluable patients
experienced local or loco-regional recurrence within
12 months and this may call for consolidation of therapy.
With tumor growth in size, erosion of cartilage happens,
which confers poor prognosis that appeared in the present analysis as well as patients with cartilage invasion
had relatively poorer PFS (16 vs. 36 months) compared to
those without cartilage erosion. However, this could not
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reach statistical significance because of small sample size.
We also attempted to investigate the impact of histology
on the outcome different prognostic variables.
Present analysis also reveals that the patients have a
favorable prognosis as median PFS and OS for the entire
cohort was 48 months and 224 months, though median
time to local or distant metastasis is 12 months only. This
also suggests that the patients merit careful regular
follow-up at three monthly intervals for at least 2 years
and six monthly thereafter with clinical examination. As
the patients predominantly fail in lung or bone a periodic
x-ray evaluation of the chest every six months may be
considered. The proposed management algorithm is
described in Figure 5.
This IPD clearly highlights that LSTS is a rare disease
with favorable survival. These tumors present early
unlike other STS and are amenable for conservative surgery also, which allows for voice preservation in many
cases. Efficacy of adjuvant radiation may be limited to
cases with adverse pathological factors or in patient with
conservative surgery. However, point should be made
that even in STS adjuvant radiation improves local disease control without much impact on survival. The present analysis is not free from limitations. Being a
retrospective individual patient data analysis, it attracts
all possible criticisms inherent to retrospective analysis.
In addition, there are missing data for different variables,
which make interpretation difficult. However, it is impossible to have large and prospective data in rare diseases.
Therefore, the present analysis aims to give a broad idea
about such a rare disease and may guide to reach a meaningful conclusion about management of such patients.

4 | CONCLUSION
LSTS is a rare disease with favorable survival. These
tumors present early unlike other STS and are amenable
for conservative surgery also, which allows for voice preservation in many cases. Adjuvant radiation may be considered for patients with high-risk factors to a dose of 60 Gy.
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